Signal Genetics, a predictive genetic testing company focused on oncology, recently announced that it would work with pharmaceutical company Array BioPharma to advance both companies’ goals of finding biomarkers for myeloma patients.
Clavis and Clovis Sign Licensing Deal for Cancer Drug
Start-up biotech Clovis Oncology has signed a $380 million deal to license an experimental pancreatic cancer drug from Norwegian company Clavis Pharma.
GenVec Receives Orphan Drug Designation, $22M Development Deal
GenVec’s experimental drug to treat pancreatic cancer has been granted orphan drug status by the U.S. Food and Drug Administration.
